Tenecteplase Before Thrombectomy at 4.5 to 24 Hours for Basilar Artery Occlusion
Rui Li, Xiaoxi Yao, Raul Gomes Nogueira, Guangxiong Yuan, Zhongjun Chen, Wenhuo Chen, Tingyu Yi, Youquan Ren, Junfeng Su, Hao Wang, Zhengfei Ma, Guoyong Zeng, Benxiao Wang, Ming Wei, Shunfu Jiang, Guodong Xiao, Cunfeng Song, Tao Cui, Yaxuan Sun, Yuwen Li, Zhiming Zhou, Xingyun Yuan, Huaizhang Shi, Guang Zhang, Jianshang Wen, Chuanqing Yu, Tao Wang, Jinglun Li, Chuyuan Ni, Fei Wang, Yu Jin, Yao Wang, Zhide Li, Lihua Xu, Bin Mei, Peiyang Zhou, Zhihua Cao, Pu Fang, Hanwen Liu, Juluo Chen, Tao Qiu, Guangsen Cheng, Jie Chen, Yi Sui, Qingbo Lu, Lei Mou, Chunrong Tao, Jun Sun, Cong Luo, Pengfei Xu and 10 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance: Among patients with moderate to severe basilar artery occlusion admitted directly to EVT-capable centers who presented 4.5 to 24 hours after stroke onset, the addition of intravenous tenecteplase before EVT did not result in improved functional outcomes compared with EVT alone.
This approach established a systematic strategy for identifying uterus-selective tocolytics, and these findings support further preclinical development of repurposed drugs and drug combinations for the treatment of preterm labor to improve pregnancy and neonatal outcomes.
Shajila Siricilla, Christopher J. Hansen, Jeremy Staub and 18 more — Science Translational Medicine
Here, we report that in the experimental autoimmune encephalitis mouse model of MS, treatment with kamuvudine-9 (K-9), an NRTI derivative with an enhanced safety profile, prevented further neurological deficits and reversed preexisting paralysis and vision loss.
Praveen Yerramothu, Kameshwari Ambati, Joseph Magagnoli and 36 more — Science Translational Medicine
PonatiLink-2 outperforms clinically relevant treatments in mouse models of BCR :: ABL1 -driven cancer, both in combination with dasatinib against wild-type BCR :: ABL1 and as a single agent against ponatinib-resistant disease.
Jack W. Stevenson, Kevin Lou, Joshua A. Reynolds and 25 more — Nature
Conclusions In this first-in-human study, a single suprachoroidal injection of AXT107 up to 0.5 mg was well tolerated through Week 40, with no drug-related serious adverse events, no clinically significant intraocular inflammation, and no sustained IOP elevations.
N. B. Pandey, A. C. Mirando, D. R. P. Almeida and 6 more — medRxiv